Opening New Frontiers By Advancing The Promise of PI Signaling Pathways

Kevan Shokat, Ph.D.

Select a team to find out more

Kevan Shokat, Ph.D.

Kevan Shokat, Ph.D.

Professor, Cellular & Molecular Pharmacology, UCSF, Department of Chemistry, UC-Berkeley, Investigator, Howard Hughes Medical Institute

Dr. Kevan Shokat is a pioneer in the development of chemical methods for investigating cellular signal transduction pathways—with a particular focus on protein kinases and lipid kinases.  He uses a combination of chemical synthesis and protein engineering to create uniquely traceable and regulatable kinases, allowing the function of over 100 different kinases to be uncovered across all disease areas including oncology, metabolism, and infectious disease.

Kevan is currently an investigator of the Howard Hughes Medical Institute.  He is also a professor in the Department of Cellular and Molecular Pharmacology at the University of California at San Francisco and in the Department of Chemistry at the University of California at Berkeley. 

After receiving a Ph.D. in organic chemistry at UC Berkeley with Professor Peter Schultz, and pursuing postdoctoral work in immunology at Stanford University with Professor Chris Goodnow, Kevan began his independent research career at Princeton University.   He has received numerous accolades that include being named a Fellow by several prestigious research foundations, such as the Pew Foundation, Searle Foundation, Sloan Foundation, Glaxo-Wellcome Foundation and the Cotrell Foundation.  Kevan was inducted into the National Academy of Sciences in 2010, and into the Institute of Medicine and the American Academy of Arts and Sciences the following year.

Kevan has successfully commercialized discoveries from his laboratory.  In 2007, he co-founded Intellikine, Inc. to commercialize a series of PI3K and mTOR small molecule inhibitors for cancer and inflammatory disease.  Intellikine progressed three compounds into Phase 1 clinical trials over a four-year span, including INK1197 (PI3Kd), INK128 (mTOR), and INK1117 (PI3Ka).  The compound INK1197 has been partnered with Infinity Pharmaceuticals. In December 2011, Intellikine was acquired by Takeda Pharmaceuticals. In 2013, Kevan co-founded Araxes Pharmaceuticals in La Jolla, Calif., and San Diego, Calif.-based eFFECTOR Pharmaceuticals.